Analyzing Lucid Diagnostics (LUCD) and Its Competitors

Lucid Diagnostics (NASDAQ:LUCD) is one of 844 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Lucid Diagnostics to similar businesses based on the strength of its dividends, profitability, analyst recommendations, earnings, institutional ownership, valuation and risk.

Profitability

This table compares Lucid Diagnostics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-959.76%	N/A	-119.57%
Lucid Diagnostics Competitors	-12,346.73%	-197.60%	-30.56%

Analyst Ratings

This is a breakdown of recent recommendations for Lucid Diagnostics and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1	0	4	0	2.60
Lucid Diagnostics Competitors	9839	15125	45459	1588	2.54

Lucid Diagnostics presently has a consensus price target of $4.19, suggesting a potential upside of 885.29%. As a group, “Biotechnology” companies have a potential upside of 99.19%. Given Lucid Diagnostics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Lucid Diagnostics is more favorable than its competitors.

Insider & Institutional Ownership

74.0% of Lucid Diagnostics shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 6.9% of Lucid Diagnostics shares are held by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Lucid Diagnostics has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, Lucid Diagnostics’ competitors have a beta of 1.10, indicating that their average stock price is 10% more volatile than the S&P 500.

Earnings and Valuation

This table compares Lucid Diagnostics and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Lucid Diagnostics	$5.45 million	-$58.01 million	-0.90
Lucid Diagnostics Competitors	$742.03 million	$14.11 million	-15.42

Lucid Diagnostics’ competitors have higher revenue and earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Lucid Diagnostics beats its competitors on 8 of the 13 factors compared.

About Lucid Diagnostics

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.